Abstract
After witnessing a slump in demand and manufacturing index due to after-impact
of economic recession, the global API market has been advancing at a
significant growth rate in recent times. The market, which is likely to
register a healthy CAGR of around 8% during 2012-2015, is supported by various
key factors, such as emergence of India and China as prominent API
manufacturing hub, patent expiration of blockbuster drugs and technological
innovation to drive HPAPI segment. Further, impressive participation of
private players is positively boosting the API production.
As per our report, "Global API Market Analysis", the focus of global
pharmaceutical and biotech industry participants is shifting towards
cost-effective and quality-driven destinations, such as India and China. These
countries provide cheap labor, high productivity, low-investment to set-up
plant, good profit margins, among others. In addition, there is a set of
supportive regulations that support the local manufacturing and at the same
time encourage export between nations. With regards to liberal competitive
scenario in India and China, the report has effectively provided a comparative
analysis among countries with respect to key indicators, such as labor cost
and productivity, price structure, and investment cost to set up plant.
It is worthy to mention here that the report takes into account those
countries that are likely to provide profitable market opportunities for API
market participants. In other words, the overall study analyzes the current
and future outlook of API exporting nations, such as India, China and Italy.
As our study shows that many countries in the world deal with API import or
manufacture less number of APIs, we have not covered them.
Our study indicates that High Potency Active Pharmaceutical Ingredients
(HPAPIs) is expected to play a major role in the future growth of global APIs
market. With a worldwide value of US$ 9.2 Billion in 2011, the HPAPI market is
growing at a CAGR of around 9% till 2015. Growth in the oncology therapeutics
market will primarily drive the market. The report, in such a context, covers
an in-depth study of global HPAPI market and bifurcate the segment by
synthesis agent, branded and generics. In addition, it also elucidates the key
developments with regards to HPAPIs in order to provide a comprehensive
analysis.
The report provides an extensive research and prudent analysis on the
worldwide API market and illustrates the industry segment into significant
manner. Separate sections on therapeutic-wise analysis and emerging
opportunities from High Potency APIs has also been covered separately in the
report. Moreover, it provides an overview of the regulatory environment. The
research contains exhaustive information on the market players, recent
developments and geographical markets that will help clients in formulating
market strategies and assess opportunity areas in the global APIs market.
Table of Contents
1. Analyst View
2. Research Methodology
3. APIs - An Introduction
4. Industry Performance
- 4.1 Current and Future Market Analysis to 2015
- 4.2 Market Segments
- 4.2.1 Branded and Generic APIs
- 4.2.2 Synthetic and Biotech APIs
- 4.3 Future Opportunity Assessment
5. Countries' Comparative Analysis: API Manufacturing
- 5.1 Labor Cost and Productivity
- 5.2 Price Structure
- 5.3 Investment Cost in Plant Set-up
6. Analysis by Therapeutic Segments
- 6.1 Central Nervous System Disorders
- 6.2 Cardiovascular Diseases
- 6.3 Diabetes
- 6.4 Respiratory Disorders
- 6.5 Oncology
7. Key Geographical Markets
- 7.1 China
- 7.1.1 Current and Future Market Analysis to 2015
- 7.1.2 Regional Segmentation
- 7.1.3 Regulatory Environment
- 7.1.4 Future Opportunity Assessment
- 7.2 India
- 7.2.1 Current and Future Market Analysis to 2015
- 7.2.2 Regional Segmentation
- 7.2.3 Regulatory Environment
- 7.2.4 Future Opportunity Assessment
- 7.3 Italy
- 7.3.1 Current and Future Market Analysis to 2015
- 7.3.2 Regulatory Environment
- 7.3.3 Future Opportunity Assessment
- 7.4 Taiwan
8. High-Potency APIs: An Emerging Opportunity
9. Regulatory Environment
10. Competitive Landscape
- 10.1 Dr Reddy's Laboratories
- 10.2 Cipla
- 10.3 Ranbaxy Laboratories
- 10.4 Zhejiang Hisun Pharmaceutical Co. Ltd.
- 10.5 Fabbrica Italiana Sintetici
- 10.6 Cambrex Corporation
- 10.7 Pfizer CentreSource
- 10.8 Teva Active Pharmaceutical Ingredients
- 10.9 Lonza
- 10.10 Daiichi Fine Chemicals
List of Figures:
- Figure 4-1: Global - API Market (Billion US$), 2011-2015
- Figure 4-2: Global - Share of Captive and Merchant Market in API Market
(2011)
- Figure 4-3: Global - API Captive Market (Billion US$), 2011-2015
- Figure 4-4: Global - API Merchant Market (Billion US$), 2011-2015
- Figure 4-5: Global - Share of Branded and Generic APIs in API Merchant
Market (2011)
- Figure 4-6: Global - Generic API Merchant Market (Billion US$), 2011-2015
- Figure 4-7: Global - Branded API Merchant Market (Billion US$), 2011-2015
- Figure 4-8: Global - Share of Synthetic and Biotech APIs in API Market
(2011)
- Figure 5-1: Global - Price Structure for Pharmaceutical Fine Chemicals in
US, India and China (%)
- Figure 7-1: China - Pharmaceutical Industry by Segment (2010)
- Figure 7-2: China - API Merchant Market (Billion US$), 2011-2015
- Figure 7-3: China - Share in Global API Merchant Market (2011)
- Figure 7-4: China - Generic API Merchant Market (Billion US$), 2011-2015
- Figure 7-5: China - Share in Global Generic API Merchant Market (2011)
- Figure 7-6: India - API Merchant Market (Billion US$), 2011-2015
- Figure 7-7: India - Share in Global API Merchant Market (2011)
- Figure 7-8: India - Generic API Merchant Market (Billion US$), 2011-2015
- Figure 7-9: India - Share in Global Generic API Merchant Market (2011)
- Figure 7-10: Italy - API Merchant Market (Billion US$), 2011-2015
- Figure 7-11: Italy - Share in Global API Merchant Market (2011)
- Figure 7-12: Italy - Number of API Producers and Manufacturing Plants
(1991, 2000 & 2009)
- Figure 7-13: Italy - Generic API Merchant Market (Billion US$), 2011-2015
- Figure 7-14: Italy - Share in Global Generic API Merchant Market (2011)
- Figure 7-15: Taiwan - API Market (Billion NT$), 2010 & 2011
- Figure 8-1: Global - HPAPI Market (Billion US$), 2011-2015
- Figure 8-2: Global - Share of Synthetic and Biotech HPAPIs in HPAPI Market
(2011)
- Figure 8-3: Global - Share of Generics and Branded in HPAPI Market (2011)
List of Tables:
- Table 3-1: Classification of Bulk Drugs
- Table 5-1: Global - Fine Chemical Industry Labor Cost and Productivity in
Key Regions (2010)
- Table 5-2: Global - Investment Cost Comparison for Multi-Purpose
Pharmaceutical Fine Chemical Plants in Key Countries
- Table 7-1: China - Number of API Companies by Province
- Table 7-2: India - Number of Bulk Drugs Manufacturing Units
- Table 7-3: Taiwan - Number of Pharmaceutical Licenses by Type (2010)
- Table 9-1: Scope of Authority for Regulatory Agencies
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
